Ranitidine
Ranitidine (ranitidine) is a small molecule pharmaceutical. Ranitidine was first approved as Zantac 150 on 1983-06-09. It is used to treat duodenal ulcer, gastroesophageal reflux, peptic esophagitis, stomach ulcer, and zollinger-ellison syndrome in the USA. The pharmaceutical is active against histamine H2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Ranitidine (discontinued: Ranitidine, Tritec, Zantac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ranitidine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZANTAC 75 | Sanofi | N-020520 DISCN | 1995-12-19 | 1 products, RLD |
| ZANTAC 75 | Sanofi | N-020745 DISCN | 1998-02-26 | 1 products, RLD |
| ZANTAC 150 | Sanofi | N-021698 DISCN | 2004-08-31 | 2 products, RLD |
| ZANTAC 150 | GSK | N-018703 DISCN | 1983-06-09 | 1 products, RLD |
| ZANTAC 300 | GSK | N-018703 DISCN | 1985-12-09 | 1 products, RLD |
| ZANTAC | GSK | N-019675 DISCN | 1988-12-30 | 1 products, RLD |
| ZANTAC 150 | GSK | N-020251 DISCN | 1994-03-31 | 2 products |
| ZANTAC 25 | GSK | N-020251 DISCN | 2004-04-01 | 1 products |
| ZANTAC 150 | GSK | N-020095 DISCN | 1994-03-08 | 1 products, RLD |
| ZANTAC 300 | GSK | N-020095 DISCN | 1994-03-08 | 1 products, RLD |
| ZANTAC | PAI Pharma | N-019090 DISCN | 1984-10-19 | 1 products, RLD |
| ZANTAC IN PLASTIC CONTAINER | PAI Pharma | N-019593 DISCN | 1986-12-17 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acid reducer | ANDA | 2020-01-15 |
| acid reducer 150 | ANDA | 2019-09-30 |
| aptidine | ANDA | 2013-02-21 |
| deramsilkrx anodynexa pak | ANDA | 2015-07-13 |
| dermasilkrx diclopak | ANDA | 2015-08-05 |
| equaline | ANDA | 2015-04-01 |
| gabitidine | unapproved drug other | 2011-08-01 |
| heratburn relief | ANDA | 2019-09-30 |
| inflammation reduction pack | ANDA | 2015-11-18 |
| ranitidine | ANDA | 2024-10-30 |
Show 15 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2780 | Injection, ranitidine hydrochloride, 25 mg |
Clinical
Clinical Trials
110 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 4 | — | 1 | — | 8 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | 1 | 3 | 1 | 1 | 6 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 3 | 3 | — | 6 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | 3 | 2 | 5 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | 1 | — | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | 1 | 1 | 3 |
| Sclerosis | D012598 | — | — | — | — | 1 | 1 | 1 | 3 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | 1 | 2 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | 1 | 1 | 2 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 2 | — | 2 |
Show 31 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 4 | 1 | — | 1 | 5 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | 1 | — | 3 | — | — | 4 |
| Esophageal neoplasms | D004938 | — | C15 | — | 2 | 1 | — | — | 3 |
| Stomach ulcer | D013276 | — | K25 | — | — | 3 | — | — | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | 1 | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | — | 1 | — | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | 1 | 1 | — | — | 1 |
| Cough | D003371 | HP_0012735 | R05 | — | — | 1 | — | — | 1 |
| Bronchial hyperreactivity | D016535 | — | — | — | — | 1 | — | — | 1 |
| Metaplasia | D008679 | — | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | 1 | 4 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 1 | — | — | 1 | 4 |
| Recurrence | D012008 | — | — | 1 | 2 | — | — | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 3 | — | — | — | 3 |
| Peritoneal neoplasms | D010534 | — | — | 1 | 3 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 2 | — | — | — | 2 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 2 | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 2 |
Show 41 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | 1 | 4 |
| Covid-19 | D000086382 | — | — | 1 | — | — | — | 1 | 2 |
| Esophagitis | D004941 | HP_0100633 | K20 | 1 | — | — | — | 1 | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | — | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Poisoning | D011041 | EFO_0008546 | T65.91 | — | — | — | — | 2 | 2 |
| Surgical anastomosis | D000714 | — | — | — | — | — | — | 2 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | — | — | — | 1 | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 1 | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | — | — | — | 1 | 1 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ranitidine |
| INN | ranitidine |
| Description | Ranitidine is a member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease. It has a role as an anti-ulcer drug, a H2-receptor antagonist, an environmental contaminant, a xenobiotic and a drug allergen. It is a member of furans, a tertiary amino compound, a C-nitro compound and an organic sulfide. |
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 |
Identifiers
| PDB | — |
| CAS-ID | 66357-35-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1790041 |
| ChEBI ID | — |
| PubChem CID | 3001055 |
| DrugBank | DB00863 |
| UNII ID | 884KT10YB7 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ranitidine – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ranitidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,204 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
427,512 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use